Completed PHASE3 INTERVENTIONAL 1-arm NCT01577732

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers

Sponsor: GlaxoSmithKline

Conditions Acellular Pertussis Diphtheria Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines Haemophilus Influenzae Type b Poliomyelitis Tetanus

Interventions Infanrix-IPV+Hib™

Updated 11 times since 2017 Last updated: Jan 3, 2020 Started: Dec 8, 2012 Primary completion: Apr 9, 2013 Completion: Apr 9, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01577732, this PHASE3 trial focuses on Acellular Pertussis and Diphtheria and remains completed. Sponsored by GlaxoSmithKline, it has been updated 11 times since 2012, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3
Sep 2018 — Feb 2020 [monthly]

Completed PHASE3
Jun 2018 — Sep 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haiphong, Vietnam